Madrigal Pharmaceuticals MDGL announced that the European Commission (EC) has granted a conditional marketing authorization to Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Madrigal Pharmaceuticals' liver ...
Hosted on MSN
Madrigal Pharmaceuticals, Inc. (MDGL)’s Rezdiffra Hits 51% Liver Stiffness Reduction in Phase 3
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is leading innovation in treating metabolic dysfunction-associated steatohepatitis (MASH), previously known as NASH. It’s FDA-approved drug, Rezdiffra ...
Artificial intelligence has dominated investor attention for two years, but biotech revenue lines are also bending sharply ...
Shares of Madrigal Pharmaceuticals (MDGL) traded sharply higher for the second straight session on Wednesday after Cantor Fitzgerald upgraded the company, arguing that the commercial rollout of its ...
CONSHOHOCKEN, Pa., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated ...
Janus Henderson Investors, an investment management company, released its “Forty Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. shares increased following ...
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is leading innovation in treating metabolic dysfunction-associated steatohepatitis (MASH), previously known as NASH. It’s FDA-approved drug, Rezdiffra ...
Madrigal Pharmaceuticals MDGL reported third-quarter 2025 loss of $5.08 per share, wider than the Zacks Consensus Estimate of a loss of $1.98. In the year-ago quarter, the company had incurred a loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results